APA
Figueroa I., Leipold D., Leong S., Zheng B., Triguero-Carrasco M., Fourie-O'Donohue A., Kozak K. R., Xu K., Schutten M., Wang H., Polson A. G. & Kamath A. V. (20190318). Prediction of non-linear pharmacokinetics in humans of an antibody-drug conjugate (ADC) when evaluation of higher doses in animals is limited by tolerability: Case study with an anti-CD33 ADC. : mAbs.
Chicago
Figueroa Isabel, Leipold Doug, Leong Steve, Zheng Bing, Triguero-Carrasco Montserrat, Fourie-O'Donohue Aimee, Kozak Katherine R, Xu Keyang, Schutten Melissa, Wang Hong, Polson Andrew G and Kamath Amrita V. 20190318. Prediction of non-linear pharmacokinetics in humans of an antibody-drug conjugate (ADC) when evaluation of higher doses in animals is limited by tolerability: Case study with an anti-CD33 ADC. : mAbs.
Harvard
Figueroa I., Leipold D., Leong S., Zheng B., Triguero-Carrasco M., Fourie-O'Donohue A., Kozak K. R., Xu K., Schutten M., Wang H., Polson A. G. and Kamath A. V. (20190318). Prediction of non-linear pharmacokinetics in humans of an antibody-drug conjugate (ADC) when evaluation of higher doses in animals is limited by tolerability: Case study with an anti-CD33 ADC. : mAbs.
MLA
Figueroa Isabel, Leipold Doug, Leong Steve, Zheng Bing, Triguero-Carrasco Montserrat, Fourie-O'Donohue Aimee, Kozak Katherine R, Xu Keyang, Schutten Melissa, Wang Hong, Polson Andrew G and Kamath Amrita V. Prediction of non-linear pharmacokinetics in humans of an antibody-drug conjugate (ADC) when evaluation of higher doses in animals is limited by tolerability: Case study with an anti-CD33 ADC. : mAbs. 20190318.